RxDoctor Payments Data

Shahan Stutes, MD

Allergy & Immunology · Oklahoma City, OKNPI 1386867646

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $28,540 of the $42,720 with a category attached, or 66.8%. Optinose US, Inc. accounts for 84.6% of it on its own, with 25 other manufacturers making up the rest.

$42,720in general payments, 2019–2025

Across 433 payments — averaging $98.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Optinose US, Inc.$36K
  • Regeneron Healthcare Solutions, Inc.$964
  • AstraZeneca$941
  • GSK$888
  • Sanofi$624
  • Alk-abello, Inc$361
  • plus $3K from 20 others

What the payments were for

  • Consulting fees$4,50011%
  • Speaking & faculty fees$28,54067%
  • Travel & lodging$1,5614%
  • Food & beverage$7,89118%
  • Education$2281%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few allergy & immunology providers in Oklahomato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$405,693
Medicare patients
231
Services billed
23,056

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent SyringeDupilumab15$54,079
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$32,892
Spiriva RespimatTiotropium Bromide22$19,820
Epinephrine101$16,887
Breo ElliptaFluticasone/Vilanterol23$13,233
Arnuity ElliptaFluticasone Furoate38$11,075
SymbicortBudesonide/Formoterol Fumarate35$10,792
XhanceFluticasone Propionate17$10,097
DuleraMometasone/Formoterol17$8,980
Advair DiskusFluticasone Propion/Salmeterol14$3,993
Advair HfaFluticasone Propion/Salmeterol11$3,624
Montelukast Sodium166$3,202
Azelastine Hcl94$2,869
Ipratropium Bromide113$2,733
Wixela InhubFluticasone Propion/Salmeterol17$2,380

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$888$57,19990 claims
Hikma Pharmaceuticals USAEpinephrine$21$16,887101 claims
AstraZenecaSymbicort$941$10,79235 claims
Optinose US, Inc.Xhance$36,132$10,09717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy & immunology providers in Oklahomaon file to place this against a meaningful peer group, so we don't.

Other allergy & immunology in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →